205
0 Kommentare
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO Annual Meeting
Molecular Residual Disease (MRD) study and multiple RiskScore studies among seven new datasets to be shared by Myriad and Collaborators
SALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and its collaborators will share data from seven studies at the 2024
ASCO Annual Meeting. Three studies led by Myriad focus on breast cancer risk assessment, and four additional studies will be shared by collaborators that will cover the company’s Precise MRD Test,
MyChoice CDx HRD Companion Diagnostic Test, and the Myriad Collaborative Research Registry (MCRR). At booth 25014, Myriad will highlight the value of genetic testing and genomic insights in guiding personalized cancer treatment decisions, as well as share
information about upcoming product innovations including MRD and liquid biopsy testing.
New Data at ASCO
Oral Presentation: Evaluation of a polygenic risk score as a predictor of early onset triple-negative breast cancer in Black women (Abstract #: 10501)
Presenter: Holly J. Pederson, MD, Director, Medical Breast Services, Cleveland Clinic
Date: Saturday, June 1, 2024
Time: 3:12 pm CT
Description: This study demonstrates that Myriad’s RiskScore improves upon clinical factors for the prediction of triple-negative breast cancer and early onset (<50 years)
triple-negative breast cancer in Black women.
Poster: Comparison of primary versus metastatic tumor tissue sources when designing panels for whole-genome-based tumor-informed ctDNA assays in clear cell renal cell
carcinoma (Abstract #3039)
Date: Saturday, June 1, 2024
Time: 9:00am – 12:00pm CT
Description: In a pilot study of patients with oligometastatic renal cell carcinoma, molecular residual disease (MRD) results were largely concordant with mortality status and
between monitoring panels composed of thousands of probes identified from either primary or metastatic tumors, suggesting repeat biopsy might not be necessary for long term MRD monitoring.
Lesen Sie auch
Poster: Improving a polygenic risk score (PRS) for breast cancer (BC) risk assessment in diverse ancestries (Abstract #: 10533)
Date: Monday, June 3, 2024
Time: 1:30 – 4:30pm CT
Description: This study highlights a new 385-SNP PRS component of RiskScore and demonstrates it is well-calibrated, improves upon clinical factors, and outperformed existing PRS in
all tested ancestries for the prediction of breast cancer risk.